JNJ stock forecast: what analysts expect
Wall Street analysts covering Johnson & Johnson currently rate the stock a Buy on average, with a mean 12-month price target of $272.50 — +4.5% versus the last price of $260.86. Targets reflect analyst opinion, not a guarantee.
JNJ historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in JNJ.
JNJ annual returns by year
Congress trading in JNJ
52 members of Congress have disclosed trading JNJ — 91 purchases and 49 sales worth an estimated $2.9M. Most recent disclosure: Jun 9, 2026.
See who in Congress traded JNJ →Insider activity in JNJ
JNJ's own executives and directors have made 0 open-market purchases ($0) and 6 sales ($24.8M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 6, 2026.
| Aug 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | $2.4M |
| Aug 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | $1.7M |
| Aug 5, 2026 | Duato Joaquin | CEO and Chairman of the Board | Sell | $10.8M |
| Aug 5, 2026 | Duato Joaquin | CEO and Chairman of the Board | Sell | $1.7M |
| Jul 20, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | $5.8M |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
JNJ Key Statistics
JNJ in plain English
- P/E ratio (30.3) — how many dollars you pay for each $1 of JNJ's yearly profit. That's a fairly normal range.
- ROE (25.74%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (21.48%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (2.05%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
JNJ stock: frequently asked questions
What is Johnson & Johnson's stock price today?
Johnson & Johnson (JNJ) last traded at $260.86 on the NYSE. Over the past 52 weeks the stock has traded between $172.72 and $274.90.
Is JNJ stock a buy or a sell?
Wall Street analysts' consensus rating on JNJ is "Buy", with an average 12-month price target of $272.50 — about +4.5% versus the current price of $260.86. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in JNJ 10 years ago be worth today?
A $1,000 investment in Johnson & Johnson made 10 years ago would be worth about $2,855 today (dividends reinvested) — a total return of 185%, or 11.1% per year.
Does JNJ pay a dividend?
Yes. Johnson & Johnson currently pays a dividend yielding about 2.05% per year at today's share price.
What is JNJ's P/E ratio?
JNJ trades at a trailing price-to-earnings ratio of 30.3, and 21.2 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade JNJ stock?
Yes — 52 members of Congress have disclosed trades in JNJ under the STOCK Act, totaling 91 purchases and 49 sales worth an estimated $2.9M.
What is Johnson & Johnson's ticker symbol?
Johnson & Johnson trades under the ticker symbol JNJ on the NYSE.
Compare JNJ with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.